+ Site Statistics
References:
54,258,434
Abstracts:
29,560,870
PMIDs:
28,072,757
+ Search Articles
+ Subscribe to Site Feeds
Most Shared
PDF Full Text
+ PDF Full Text
Request PDF Full Text
+ Follow Us
Follow on Facebook
Follow on Twitter
Follow on LinkedIn
+ Translate
+ Recently Requested

Statin drugs and risk of advanced prostate cancer



Statin drugs and risk of advanced prostate cancer



Journal of the National Cancer Institute 98(24): 1819-1825



Statins are commonly used cholesterol-lowering drugs that have proapoptotic and antimetastatic activities that could affect cancer risk or progression. Results from previous epidemiologic studies of the association between statin use and cancer have been inconsistent. We investigated the association of statin use with total and advanced prostate cancer, the latter being the most important endpoint to prevent. We analyzed data from an ongoing prospective cohort study of 34,989 US male health professionals who were cancer free in 1990 and were followed to 2002. Participants reported their use of cholesterol-lowering drugs on biennial questionnaires. Prostate cancer diagnosis was confirmed by medical record review. Multivariable-adjusted relative risks (RRs) were estimated from Cox proportional hazards regression models. Statistical tests were two-sided. During 376,939 person-years of follow-up, we ascertained 2579 prostate cancer cases, 316 of which were advanced (regionally invasive, metastatic, or fatal). The age-standardized incidence rates of advanced prostate cancer were 38 and 89 per 100,000 person-years in current statin users and in past or never users, respectively. The multivariable-adjusted relative risk of advanced disease was 0.51 (95% confidence interval [CI] = 0.30 to 0.86) and of metastatic or fatal disease was 0.39 (95% CI = 0.19 to 0.77) for current statin use compared with no current use. The associations remained after adjusting for prostate-specific antigen screening history (advanced disease: RR = 0.57, 95% CI = 0.30 to 1.11; metastatic or fatal disease: RR = 0.35, 95% CI = 0.14 to 0.92). Risk of advanced disease was lower with longer statin use (P(trend) = .003); compared with never use, the relative risk for less than 5 years of use was 0.60 (95% CI = 0.35 to 1.03) and for 5 or more years of use was 0.26 (95% CI = 0.08 to 0.83). We found no association between statin use and risk of total prostate cancer (RR = 0.96, 95% CI = 0.85 to 1.09). In this cohort of male health professionals, use of statin drugs was not associated with risk of prostate cancer overall but was associated with a reduced risk of advanced (especially metastatic or fatal) prostate cancer.

(PDF emailed within 0-6 h: $19.90)

Accession: 012889091

Download citation: RISBibTeXText

PMID: 17179483

DOI: 10.1093/jnci/djj499


Related references

Re: Statin drugs and risk of advanced prostate cancer (PC) - Platz. 2007

Words of wisdom. Re: Statin drugs and risk of advanced prostate cancer (PC). European Urology 52(4): 1258-1259, 2007

Re: Statin drugs and risk of advanced prostate cancer (PC) - Platz Ea, Leitzmann MF, Visvanathan K, Rimm EB, Stampfer MJ, Willett WC, Giovannucci E J Natl Cancer Inst 2006;98 : 1819-25. 2007

Epidemiologic musing on statin drugs in the prevention of advanced prostate cancer. Cancer Epidemiology, Biomarkers & Prevention 16(11): 2175-2180, 2007

Minimal detection bias in the inverse association between statin drug use and advanced prostate cancer risk: a simulation study. Cancer Epidemiology 35(4): E6-11, 2012

The association between metabolic syndrome and the risk of prostate cancer, high-grade prostate cancer, advanced prostate cancer, prostate cancer-specific mortality and biochemical recurrence. Journal of Experimental and Clinical Cancer Research 32: 9, 2013

Nonsteroidal antiinflammatory drugs and decreased risk of advanced prostate cancer: modification by lymphotoxin alpha. American Journal of Epidemiology 164(10): 984-989, 2006

Chemotherapy at First Diagnosis of Advanced Prostate Cancer - Revolution or Evolution? Findings from a British Uro-oncology Group UK Survey to Evaluate Oncologists' Views on First-line Docetaxel in Combination with Androgen Deprivation Therapy in Castrate-sensitive Metastatic and High-risk/Locally Advanced Prostate Cancer. Clinical Oncology ) 28(6): 376-385, 2017

Statin and NSAID use and prostate cancer risk. Pharmacoepidemiology and Drug Safety 19(7): 752-755, 2010

Statin use and the risk of breast and prostate cancer. Epidemiology 13(3): 262-267, 2002

Statin Use and Risk of Prostate Cancer in MrOS. 2012

Statin use and the risk of prostate-specific antigen recurrence after radiation therapy with or without hormone therapy for prostate cancer. Journal of Clinical Oncology 28(16): 2651-2652, 2010

Association of type 2 diabetes susceptibility variants with advanced prostate cancer risk in the Breast and Prostate Cancer Cohort Consortium. American Journal of Epidemiology 176(12): 1121-1129, 2013

African-American men are at increased risk for presenting with clinically advanced prostate cancer Results from the prostate cancer outcomes study. JGIM 14(SUPPL 2): 39, April, 1999

Statin drug use is not associated with prostate cancer risk in men who are regularly screened. Journal of Urology 192(2): 379-384, 2014